[1]贾运时,刘琪,马秀娟,等.益气固肾汤辅助奥普力农治疗慢性充血性心力衰竭患者的临床观察[J].西部中医药,2025,38(03):139-143.[doi:10.12174/j.issn.2096-9600.2025.03.27]
　JIA Yunshi,LIU Qi,MA Xiujuan,et al.Clinical Observation on Benefiting-Qi Strengthening-kidney Decoction Supplemented with Olprinone in the Treatment of Chronic Congestive Heart Failure[J].Western Journal of Traditional Chinese Medicine,2025,38(03):139-143.[doi:10.12174/j.issn.2096-9600.2025.03.27]
点击复制

益气固肾汤辅助奥普力农治疗慢性充血性心力衰竭患者的临床观察()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
38
期数:
2025年03期
页码:
139-143
栏目:
衷中参西
出版日期:
2025-03-15

文章信息/Info

Title:
Clinical Observation on Benefiting-Qi Strengthening-kidney Decoction Supplemented with Olprinone in the Treatment of Chronic Congestive Heart Failure
作者:
贾运时, 刘琪, 马秀娟, 宋温婷, 付玉娜
石家庄市中医院，河北 石家庄 050051
Author(s):
JIA Yunshi, LIU Qi, MA Xiujuan, SONG Wenting, FU Yuna
Shijiazhuang Hospital of Traditional Chinese Medicine, Shijiazhuang 050051, China
关键词:
充血性心力衰竭; 益气固肾汤; 奥普力农
Keywords:
congestive heart failure; benefiting- strengthening-kidney decoction; olprinone
分类号:
R256.21
DOI:
10.12174/j.issn.2096-9600.2025.03.27
文献标志码:
B
摘要:
目的观察自拟益气固肾汤辅助奥普力农对慢性充血性心力衰竭患者的影响。 方法将慢性充血性心力衰竭患者114例，按随机数字表法分为对照组和观察组各57例。对照组予奥普力农治疗，观察组在对照组基础上予自拟益气固肾汤治疗，两组均连续治疗7天。观察两组患者治疗前后左室舒张末期内径（left ventricular end-diastolic diameter，LVDD）、左室收缩末期内径（left ventricular end systolic diameter，LVSD）、左室射血分数（left ventricular ejection fraction，LVEF）、左室短轴缩短率（left ventricular fraction shortening，LVFS）、心血输出量（cardiac output，CO）、6 min步行试验改善情况；比较两组患者治疗前后血清N末端B型钠尿肽前体（N-terminal pro-B-type natriuretic peptide，NT-proBNP）、内皮素1（Endothelin-1，ET-1）表达水平、临床疗效和症状积分变化情况。 结果治疗后两组患者LVDD、LVSD均降低，LVEF、LVFS、HO均升高（P＜0.05），且观察组上述指标改善程度优于对照组（P＜0.05）；6 min步行距离均延长，且观察组改善程度更明显（P＜0.05）；血清NT-proBNP及ET-1表达水平均降低，且观察组降低程度更显著（P＜0.05）；观察组总有效率［94.74%（54/57）］高于对照组［80.70%（46/57）］（P＜0.05）；临床症状评分均降低，且观察组降低更明显（P＜0.05）。 结论益气固肾汤辅助奥普力农治疗慢性充血性心力衰竭能改善患者心功能，提高疗效，且能降低血清NT-proBNP及ET-1表达水平。
Abstract:
ObjectiveTo observe curative effects of selfmade benefiting-Qi strengthening-kidney decoction (YiQi Gushen Tang) as adjuvant therapy of olprinone in the treatment of chronic congestive heart failure (CHF). MethodsAll 114 CHF patients were allocated to the control group and the observation group in light of random number table method (n=57 cases in each). The control group was treated with olprinone, and the observation group took the decoction on the foundation of the therapy of the control group, both groups were treated for seven days consecutively. To observe the improvements of LVDD, LVSD, LVEF, LVFS, CO and six-minute walk test (6MWT) before and after the treatment in the two groups; to compare the expression of NT-proBNP and ET-1, clinical effects and the symptom scores before and after the treatment between the two groups. ResultsAfter the treatment, LVDD and LVSD were lowered in the two groups, while LVEF, LVFS and CO were elevated (P<0.05), and the improvements of the indexes of the observation group were better than these of the control group (P<0.05); 6MWD was lengthened, and the improvements of the observation group were more evident (P<0.05); the expressions of serum NT-proBNP and ET-1 were decreased, and the reduction of the observation group was significant (P<0.05); total effective rate of the observation group was [94.74%(54/57)], higher than [80.70%(46/57)] of the control group (P<0.05); the scores of clinical symptoms were reduced, and the decrease of the observation group was more obvious (P<0.05). ConclusionBenefiting-Qi strengthening-kidney decoction supplemented with olprinone in the treatment of chronic CHF could improve cardiac function and TCM therapeutic effects, and lower the expressions of serum NT-proBNP and ET-1.

备注/Memo

备注/Memo:
贾运时（1983—），男，硕士学位，主治医师。研究方向：心血管疾病的临床诊治。Email：kouqiao7078316@163.com。河北省卫生健康委员会科研计划项目（20200007）；河北省中医药类科研计划课题项目（2019441）。
更新日期/Last Update: 2025-03-15